SPY002-072

SPY072 (internal code SPY002-072) is Spyre Therapeutics' half-life extended anti-TL1A antibody, and it represents the first serious push of the TL1A mechanism outside inflammatory bowel disease. The Phase 2 SKYWAY basket trial (NCT07148414) finished enrolling 285 patients across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), and Spyre has accelerated the RA sub-study topline to Q3 2026, with PsA and axSpA readouts expected in Q4 2026 [1][2]. If a signal shows in RA, where TNF blockers have owned the market for two decades, Spyre expands from an IBD story into a broader immunology franchise. If it flops, the rheum bet dies and SPY002 goes back to being an IBD asset behind Merck and Sanofi.

SPY072 is a novel compound with no approvals anywhere. The lead study, SKYWAY, is a Phase 2 randomized placebo-controlled trial in adult patients with moderately-to-severely active RA, PsA, or axSpA who had inadequate response to conventional or advanced therapies, sponsored by Spyre Therapeutics (NASDAQ: SYRE) [1]. That prior-failure enrichment matters: it narrows the trial to a refractory population where the commercial bar is lower but the biological bar is higher, since these patients have already failed at least one validated mechanism. A separate Phase 1 healthy-volunteer study (NCT06622070, n=56) supports the PK profile of the half-life extended format [3]. The SKYWAY basket has closed enrollment at 285 patients, and in March 2026 Spyre pulled the RA sub-study readout forward to Q3 2026 (Week 12 topline), with PsA and axSpA sub-studies expected Q4 2026 [2][4]. No FDA designations, no breakthrough, no fast track, no orphan status apply to this program. That's expected: those designations track high-unmet-need or rare settings, and RA/PsA/axSpA all have multiple approved biologics and oral options. Spyre reported $1.2 billion in pro forma cash and marketable securities as of Q1 2026, with runway into 2H 2029, so a positive Phase 2 could be advanced into Phase 3 without an emergency raise [5].

TL1A is a cytokine, a signaling protein that immune cells release to rev up other immune cells. It binds a receptor called DR3 (TNFRSF25) on T cells, making them more responsive to IL-2 and pushing them to proliferate and secrete inflammatory signals [6]. Think of TL1A as an amplifier that turns a low-grade T-cell response into a sustained inflammatory attack, and its blockade dials the volume back without wiping out the immune system the way broader immunosuppressants do. Human genetics support the target: variants in the TNFSF15 gene are linked to Crohn's disease, ulcerative colitis, and ankylosing spondylitis, so real people with real TL1A biology already develop these diseases [7]. The commercial validation is louder than the science on its own would suggest. Merck paid $10.8 billion for Prometheus Biosciences in 2023 to acquire tulisokibart, another anti-TL1A antibody, primarily for IBD [8]. Sanofi paid Teva $500 million upfront plus up to $1 billion in milestones on October 3, 2023 for duvakitug (TEV-48574), a third anti-TL1A [9]. Spyre's differentiation is a half-life extension: the antibody is Fc-engineered to bind the neonatal Fc receptor (FcRn) more tightly at endosomal pH, which recycles IgG back into circulation instead of letting it degrade in lysosomes. This is the same general class of engineering behind YTE- and LS-modified antibodies used in RSV and COVID prophylaxis. Spyre has not publicly disclosed which specific Fc mutations SPY072 carries, but the resulting PK supports dosing every 8-12 weeks rather than monthly, which matters commercially in chronic inflammation. What's not yet validated: whether blocking TL1A moves the needle in seropositive RA (patients who test positive for rheumatoid factor or anti-CCP antibodies, markers of more aggressive, erosive disease) or spondyloarthritis, where TNF, IL-17, and IL-23 blockers already work.

SKYWAY (NCT07148414) is a Phase 2 basket study across three rheumatologic diseases: RA, PsA, and axSpA. The RA cohort primary endpoint is change from baseline in DAS28-CRP at Week 12. DAS28-CRP is a composite score built from swollen joint count, tender joint count, patient global assessment, and C-reactive protein levels, and it's the standard efficacy readout that regulators and rheumatologists both accept [1]. The PsA cohort uses ACR20 response (a 20% improvement across the American College of Rheumatology criteria), and the axSpA cohort uses ASDAS/BASDAI (validated composite disease activity scores for spondyloarthritis). Enrollment target was 285, and the study is now active-not-recruiting, so the sample is locked [1]. The basket design is efficient for a mechanism that plausibly works across related inflammatory conditions, but it dilutes statistical power within any single cohort, so per-disease effect sizes will read out with wider confidence intervals than a dedicated RA-only trial would produce. The study is placebo-controlled with no active comparator, which is typical for a Phase 2 proof-of-concept but means Spyre will need a Phase 3 head-to-head or add-on-to-methotrexate design to convince payers. No biomarker enrichment strategy is described. That's a real gap. TL1A biology suggests that patients with elevated soluble TL1A or specific TNFSF15 genotypes might respond better, and Prometheus/Merck built a companion diagnostic strategy around exactly this hypothesis in IBD [8]. Spyre's decision to run an unenriched basket is either a bet that TL1A blockade works broadly, or a Phase 2 constraint that a Phase 3 program would tighten.

Our model estimates a 7% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 30%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase; it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the biggest concern. TL1A is validated in IBD, where it drives fibrostenosis (scar-tissue formation that can permanently narrow the intestine) and gut-specific T-cell dysfunction, but RA and spondyloarthritis are dominated by different cytokine circuits (TNF, IL-6, IL-17, IL-23). No prior Phase 2 has shown that blocking TL1A moves DAS28-CRP in RA, so this is a genuine biological bet, not a derivative one. The basket design without biomarker enrichment adds heterogeneity that can wash out a real but modest signal. Safety risk looks manageable but not zero. Anti-TL1A antibodies in IBD trials have shown clean profiles at the doses tested, with no dose-limiting toxicities disclosed for tulisokibart or duvakitug [8][9]. Half-life extension can raise infection risk in prolonged immune suppression, and rheumatology patients often layer biologics with methotrexate, so infection surveillance in Phase 3 will matter. Execution risk is low: Spyre has capital ($1.2B, runway to 2H 2029) and a defined enrollment cohort [5]. Commercial risk is where this gets ugly even with a positive readout. RA has biosimilar adalimumab (near-generic copies of the original Humira antibody) at heavily discounted pricing, JAK inhibitors that patients can swallow rather than inject, and IL-6 and IL-17 blockers with mature safety records. A quarterly-dosed anti-TL1A needs a compelling efficacy or safety edge, or a defined refractory subpopulation, to justify premium pricing against that competition.

Worth watching, and the readout is close. The specific data point that matters is placebo-adjusted change from baseline in DAS28-CRP in the RA cohort at Week 12, expected topline Q3 2026 [2]. Published minimal clinically important difference (MCID) estimates for DAS28-CRP range roughly 0.6 to 1.2 units depending on baseline severity and the validation study used (Wells et al. and related ACR-adjacent work), so a placebo-adjusted delta at or above ~1.0 with a clean safety profile would put SPY072 firmly in the range of currently approved biologics and revalue SYRE materially. A delta clearly below 0.6 with wide confidence intervals is a failed proof-of-concept for TL1A in rheumatology, and Spyre pivots resources back to its IBD program (SPY001, anti-a4b7) where the mechanism has clearer support. PsA (ACR20) and axSpA (ASDAS/BASDAI) sub-studies read out Q4 2026 and will indicate whether TL1A blockade generalizes across spondyloarthritis or is disease-specific [2]. Spyre is a small-cap immunology company built specifically to differentiate on half-life extension across validated inflammation targets, so this readout is a referendum on the company's core technical thesis, not just one asset. The Merck and Sanofi deals in the TL1A space mean any Spyre readout is watched by two very deep-pocketed acquirers with strategic reasons to own the pipeline if the data support cross-indication utility [8][9]. That optionality matters for SYRE's downside case even if the RA data are middling.